Wilding G - Search Results

1

Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.

Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzomanian R, Alberti D, Feierabend C, Binger K, Wilding G. Liu G, et al. Among authors: wilding g. Clin Cancer Res. 2002 Mar;8(3):706-11. Clin Cancer Res. 2002. PMID: 11895899 Clinical Trial.

2

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.

Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Bailey H, et al. Among authors: wilding g. Invest New Drugs. 1992 Nov;10(4):279-87. doi: 10.1007/BF00944182. Invest New Drugs. 1992. PMID: 1487401 Clinical Trial.

3

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR. Bailey H, et al. Among authors: wilding g. Cancer Chemother Pharmacol. 1992;30(4):297-302. doi: 10.1007/BF00686299. Cancer Chemother Pharmacol. 1992. PMID: 1643698 Clinical Trial.

4

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G. Bailey H, et al. Among authors: wilding g. Cancer Res. 1991 Feb 15;51(4):1105-8. Cancer Res. 1991. PMID: 1705165 Clinical Trial.

5

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

Bailey H, Mulcahy RT, Tutsch KD, Rozental JM, Alberti D, Arzoomanian RZ, Tombes MB, Trump DL, Wilding G. Bailey H, et al. Among authors: wilding g. Cancer Res. 1991 Feb 15;51(4):1099-104. Cancer Res. 1991. PMID: 1825475 Clinical Trial.

6

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. Berlin J, et al. Among authors: wilding g. Invest New Drugs. 1994;12(2):137-41. doi: 10.1007/BF00874444. Invest New Drugs. 1994. PMID: 7860231 Clinical Trial.

7

Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.

Rago RP, Miles JM, Sufit RL, Spriggs DR, Wilding G. Rago RP, et al. Among authors: wilding g. Cancer. 1994 Apr 1;73(7):1954-9. doi: 10.1002/1097-0142(19940401)73:7<1954::aid-cncr2820730729>3.0.co;2-h. Cancer. 1994. PMID: 8137223 Clinical Trial.

8

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Bailey HH, et al. Among authors: wilding g. J Clin Oncol. 1994 Jan;12(1):194-205. doi: 10.1200/JCO.1994.12.1.194. J Clin Oncol. 1994. PMID: 8270977 Clinical Trial.

9

Evidence of an absorption phase after short intravenous suramin infusions.

Hutson PR, Tutsch K, Spriggs D, Christian M, Rago R, Mutch R, Wilding G. Hutson PR, et al. Among authors: wilding g. Cancer Chemother Pharmacol. 1993;31(6):495-9. doi: 10.1007/BF00685042. Cancer Chemother Pharmacol. 1993. PMID: 8453691 Clinical Trial.

10

Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.

Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G. Love RR, et al. Among authors: wilding g. J Natl Cancer Inst. 1993 May 5;85(9):732-7. doi: 10.1093/jnci/85.9.732. J Natl Cancer Inst. 1993. PMID: 8478959 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

551 results

Search Page

Filters